chiasma
reinforces
commitment
people
acromegaly
advocacy
organizations
acromegaly
awareness
day
needham
globe
newswire
chiasma
nasdaq
chma
today
recognizes
acromegaly
awareness
day
observed
every
year
november
reiterates
commitment
people
acromegaly
patient
advocacy
groups
ongoing
efforts
increase
awareness
acromegaly
support
unique
needs
people
living
acromegaly
chiasma
also
host
facebook
live
event
sunday
november
et
titled
tips
achieve
effective
communications
healthcare
live
event
moderated
jill
sisco
president
acromegaly
community
jill
joined
chris
yedinak
dnp
mn
rn
grad
assistant
professor
department
neurological
surgery
pituitary
center
oregon
health
sciences
university
portland
oregon
elaine
patient
living
acromegaly
public
encouraged
watch
use
hashtag
askaboutacromegaly
show
support
event
accessible
via
link
https
mycapssa
proud
continue
unwavering
commitment
people
acromegaly
advocacy
groups
working
help
raise
awareness
significant
burdens
patients
families
bear
day
said
raj
kannan
chief
executive
officer
chiasma
acromegaly
awareness
day
reflect
years
research
innovation
made
possible
chiasma
offer
new
oral
therapeutic
option
patients
united
states
time
continuing
development
work
goal
making
novel
oral
therapy
available
acromegaly
patients
acromegaly
acromegaly
typically
develops
benign
tumor
pituitary
gland
produces
much
growth
hormone
ultimately
leading
significant
health
problems
common
features
acromegaly
facial
changes
intense
headaches
joint
pain
impaired
vision
enlargement
hands
feet
tongue
internal
organs
serious
health
conditions
associated
progression
acromegaly
include
type
diabetes
hypertension
respiratory
disorders
cardiac
cerebrovascular
disease
chiasma
estimates
approximately
adult
acromegaly
patients
chronically
treated
somatostatin
analog
injections
united
states
chiasma
chiasma
commercial
stage
biopharmaceutical
company
focused
developing
commercializing
oral
therapies
improve
lives
patients
face
challenges
associated
existing
treatments
rare
serious
chronic
diseases
employing
transient
permeability
enhancer
technology
platform
chiasma
seeks
develop
oral
medications
currently
available
injections
june
chiasma
received
fda
approval
mycapssa
maintenance
therapy
acromegaly
patients
responded
tolerated
treatment
octreotide
lanreotide
mycapssa
first
oral
somatostatin
analog
approved
fda
available
commercial
sale
chiasma
headquartered
needham
wholly
owned
subsidiary
israel
mycapssa
tpe
chiasma
registered
trademarks
chiasma
information
please
visit
company
website
investor
relations
corporate
communications
ashley
robinson
lifesci
advisors
llc
arr
media
relations
patrick
bursey
lifesci
communications
pbursey
